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Nucleoside analogues possessing hydroxamate moiety were prepa-
red from secouridine derivatives oxidized at C(2’)-position. 3’,5’-O-
Isopropylidene-2’,3’-secouridine was oxidized with CrO3/py com-
plex to the carboxylate level and with DMSO/DCC to the aldehyde
level. Both compounds (precursors) gave C(2’)-nucleoside hydroxa-
mic acids in the reaction with hydroxylamine or nitrosobenzene in
the presence of Fe3+ ions, respectively.
A number of hydroxamic acid analogues have been shown to inhibit
DNA synthesis by inactivating the enzyme ribonucleotide reductase
(RNR).1¿4 This metaloenzyme catalyzes the conversion of (ribo)nucleotides
to deoxy(ribo)nucleotides and is therefore a potential target for the develop-
ment of anticancer agents.5¿8 Hydroxamic acid moiety, R¿CONHOH, is
found to be the essential pharmacophore in the hydroxyurea, a clinically
useful inhibitor of ribonucleotide reductase.9 A variety of nucleoside ana-
logues are also active as inhibitors of ribonucleotide reductase,10¿12 follow-
ing the inhibition mechanism similar to that proposed for hydroxama-
tes.13¿15 These results have initiated our interest in the design and synthesis
of the nucleoside analogues incorporating hydroxamate moiety. A similiar
concept was devised by Farr et al.16 Their compounds inhibited RNR activ-
ity, but were 10-fold less potent than hydroxyurea. We, therefore, rational-
ize that hydroxamate-nucleoside analogues which more closely resemble the
RNR substrates should be prepared. Moreover, recent reports17¿19 that
hydroxamate compounds increase the potency of nucleosides against HIV-1
give an additional importance to derivatives combining the structural fea-
CROATICA CHEMICA ACTA CCACAA 71 (1) 119¿124 (1998)
tures of the above compounds. To prepare hydroxamic-nucleoside derivati-
ves, we have used secouridine-2’,3’-dialdehyde as the starting material. We
have already reported preliminary results on the reaction of nitrosobenzene
with 2’,3’-secouridine dialdehyde giving hydroxamic-nucleoside product.20 It
is shown that this reaction does not proceed in the absence of ferric ion un-
der the conditions employed. In the presented work, we also prepared mono-
aldehyde form 3 of 2’,3’-secouridine 1 (Scheme 1) in order to prevent the for-
mation of cyclic hemiacetals of dialdehyde monohydrate.21,22
3’,5’-O-Isopropylidene-2’,3’-seconucleoside 2 was obtained according to
the procedure described by Jones et al.23 The oxidation of 2 to the aldehyde
level was performed by dimethylsulfoxide (DMSO) and dicyclohexylcarbo-
diimide (DCC) in the presence of pyridinium trifluoroacetate (PTFA).24 The
aldehyde product 3 was obtained in 60% yield. In the NMR spectra of 3 the
signals of aldehyde proton at 10.30 ppm and aldehyde carbon at 194.20 ppm
were present, although the compound exists predominately as hydrate 3a.
The test with dinitrophenylhydrazine was positive.
In the reaction of aldehyde 3 with nitrosobenzene, we have observed in
UV spectrum the appearance of the highly characteristic peak at 520 nm
due to the formation of the iron(III)-mono-N-phenylhydroxamate complex 4.
The reaction was promoted both with proton and Fe3+ ions. Anyway, the
presence of Fe3+ in the reaction mixture made it difficult to isolate a free
hydroxamic-nucleoside conjugate from complex product 4. This is due to the
known property of hydroxamates to form a strong complex with Fe3+.25,26 To
circumvent this difficulty, we have applied a different approach to the syn-
thesis of hydroxamic-nucleoside derivatives (Scheme 2).
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Scheme 1. a) acetone, H+, RT, 2 h; b) DMSO/benzene/pyridine, TFA and DCC, RT,
overnight; c) Fe3+, H+, PhNO in acetone, RT, 6 h.
One-step oxidation of primary alcohol 2 to the corresponding carboxylic
tert-butyl ester 527 was performed using chromium trioxide-pyridine com-
plex28 in dichloromethane-dimethylformamide (4:1) in the presence of tert-bu-
tanol and acetic anhydride (60% yield). 10% of the starting compound and
15% of acetylated by-product, 2’-acetyl-3’,5’-O-isopropylidene-2’,3’-secouridi-
ne (6), were also isolated from the reaction mixture. Omission of dimethyl-
formamide from the reaction mixture led to poorer solubility of the oxidizing
complex and consequently to slower oxidation. Therefore, in dichlorometha-
ne, the yield of oxidized product 5 was diminished (26%) and the ratio of
acetylated product 6 doubled.
5’-O-Trityl-2’,3’-secouridine 7 (Scheme 3.) could not be oxidized to tert-
-butyl carboxylates at C(2’) and/or C(3’) position by this method, presumably
because of the complex cyclic hemiacetal structures of intermediary dialde-
hydes.21,22 The only isolated products were the acetylated starting compound,
2’,3’-di-O-acetyl-2’,3’-secouridine (8), and 1-[2(S)-trityloxymethyl-3(R,S)-
-acetoxy-1,4-dioxan-6(R)-yl]uracil (9). 1,4-Dioxacyclohexane structure 9 is a
diastereomeric mixture resulting from acetylation of the previously formed
intramolecular aldehyde hemiacetal. Also, an attempt at oxidation of 5’-O-
-trityl-2’,3’-secouridine dialdehyde 10 resulted only in a complex mixture of
diastereoisomeric cyclic acetals.
The method used for the preparation of 2’-hydroxamate derivative 11
(Scheme 2.) is similar to that described for the synthesis of the first sugar-
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Scheme 2. a) CrO3/pyridine complex in CH2Cl2-DMF, AcOAc, t-butanol, RT, 20 h; b)
NH2OH in MeOH, RT, 3 h; c) 40% AcOH, RT, 3 h.
hydroxamic acid.29 Solution of sodium methoxide was added to hydroxyl-
amine hydrochloride to prepare a free hydroxylamine. After removing so-
dium chloride by filtration hydroxylamine was reacted with tert-butyl-
-3’,5’-O-isopropylidene-2’,3’-secouridine-2’-carboxylate 5 giving 3’,5’-O-iso-
propylidene-2’,3’-secouridine-2’-hydroxamic acid 11 (65% yield). Deprotec-
tion was achieved in 40% acetic acid for 3 hours at room temperature giving
hydroxamic-nucleoside derivative 1230 (65% yield). As far as we know, it is
the first seconucleoside analogue incorporating hydroxamic moiety. We are
continuing investigations on hydroxamic-nucleoside analogues with other
nucleobases. Metal coordination properties and biological testing of com-
pounds described will be reported in due course.
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Prvi derivati hidroksamskih sekonukleozida
Valerije Vr~ek, Vesna ^aplar i Stanko Ur{i}
Nukleozidni derivati s hidroksamskom skupinom pripravljeni su iz sekouridina
oksidiranog na polo`aju C(2’). 3’,5’-O-Izopropiliden-2’,3’-sekouridin oksidiran je s po-
mo}u kompleksa CrO3/piridin do karboksilata, a pomo}u DMSO/DCC do aldehida.
Karboksilatni derivat u reakciji s hidroksilaminom, odnosno aldehidni derivat u re-
akciji s nitrozobenzenom u prisutnosti iona Fe3+ daje C(2’)-hidroksamski nukleozid.
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